Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Name
Jacks_Requirement for NF-kappa.pdf
Size
1.62 MB
Format
Adobe PDF
Checksum (MD5)
c7b3906b0206a1556bc6f5fc4155ff1a
Author(s)
Meylan, Etienne
Feldser, David M.
Shen, Lynn
Turk, Erin
Ouyang, Chensi
Dooley, Alison L.
Jacks, Tyler E
Date Issued
October 2009
Journal
Nature
Publisher
Nature Publishing Group
Citation
Meylan, Etienne, Alison L. Dooley, David M. Feldser, Lynn Shen, Erin Turk, Chensi Ouyang, and Tyler Jacks. “Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma.” Nature 462, no. 7269 (October 21, 2009): 104-107.
Version
Author's final manuscript
Abstract
NF-κB transcription factors function as crucial regulators of inflammatory and immune responses as well as of cell survival. They have also been implicated in cellular transformation and tumorigenesis. However, despite extensive biochemical characterization of NF-κB signalling during the past twenty years, the requirement for NF-κB in tumour development in vivo, particularly in solid tumours, is not completely understood. Here we show that the NF-κB pathway is required for the development of tumours in a mouse model of lung adenocarcinoma. Concomitant loss of p53 (also known as Trp53) and expression of oncogenic Kras(G12D) resulted in NF-κB activation in primary mouse embryonic fibroblasts. Conversely, in lung tumour cell lines expressing Kras(G12D) and lacking p53, p53 restoration led to NF-κB inhibition. Furthermore, the inhibition of NF-κB signalling induced apoptosis in p53-null lung cancer cell lines. Inhibition of the pathway in lung tumours in vivo, from the time of tumour initiation or after tumour progression, resulted in significantly reduced tumour development. Together, these results indicate a critical function for NF-κB signalling in lung tumour development and, further, that this requirement depends on p53 status. These findings also provide support for the development of NF-κB inhibitory drugs as targeted therapies for the treatment of patients with defined mutations in Kras and p53.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike 3.0
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/nature08462
